| Old Articles: <Older 7551-7560 Newer> |
|---|
 |
The Motley Fool
June 17, 2011
Seth Jayson |
A Hidden Reason the Future Looks Bright for Hi Tech Pharmacal Although Hi Tech Pharmacal shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon.   |
BusinessWeek
June 16, 2011
Ben Paynter |
The Big Business of Synthetic Highs Synthetic drugs that use legal compounds but mimic the highs of everything from marijuana to cocaine are proliferating among do-it-yourself pharma labs across the country. Bad trips - and fatal side effects - are increasing, too. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
The Motley Fool
June 16, 2011
Brian Orelli |
Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA. |
The Motley Fool
June 16, 2011
Brian Orelli |
No Poke in the Eye Here What's the biggest sign that the Food and Drug Administration is all set to approve Regeneron Pharmaceuticals' Eylea? The briefing documents for the advisory committee contained a proposed version of the label. |
The Motley Fool
June 16, 2011
Jordan DiPietro |
Should You Retire With Unitedhealth Group? Does this company have the traits of a good retirement stock? It has passed 4 of the 4 tests, which is pretty impressive. |
The Motley Fool
June 16, 2011
Dee Gill |
Teleflex, Focusing on Medical Devices, Appears Headed to Higher Valuations Teleflex's remake is an opportunity to get in on an established medical devices company -- a rebounding sector with growth potential -- for the price of the diversified company it once was. |
The Motley Fool
June 15, 2011
Brian Orelli |
Which Path Will Spectrum Pharmaceuticals Take? Spectrum Pharmaceuticals asked its shareholders to increase the number of authorized shares from 100 million to 175 million. Two days later, the company announced the repurchase of $25 million in shares. Confused? |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
The Motley Fool
June 15, 2011
Brian Orelli |
Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story. |
| <Older 7551-7560 Newer> Return to current articles. |
